Charles River Laboratories Intl. Inc vs SPDR Gold Trust — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while SPDR Gold Trust trades at $372.76. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| CRL | GLD | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | — |
52-Week High | $233.60 | $495.90 |
52-Week Low | $145.57 | $300.96 |
Enterprise Value | $14.00B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GLD trades at $367.13, down 2.59% amid a bearish technical setup with 19 sell signals versus 2 buys. Support lies at $365 and $363, while resistance is at $370 and $374. Recent news highlights gold's volatility from inflation data and Fed policy shifts, with prices testing key levels after softer CPI provided temporary relief.
The outlook remains cautious as rising yields and dollar strength pressure gold. Near-term direction hinges on Fed rate expectations and geopolitical tensions. Risks include prolonged high rates eroding gold's appeal, while potential inflation spikes or market instability could renew safe-haven demand.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →